

References

I-11

1. Estemalik E, Tepper S, Preventative treatment in migraine and the new US guidelines. *Neuropsychiatric Dis Treat*. 2013;(9):709-720.
2. Rothrock J, Bloudek L, Houle T, et al. Real world economic impact of onabotulinumtoxinA in patients with chronic migraine. The University of Alabama School Medicine, Allergan INC, Wake Forest University School of Medicine, et al.
3. Bumb A, Seifert B, Wetzel S, et al. Patients profiling for Botox®(onabotulinum toxin A) treatment for migraine a look at white matter lesions in the MRI as a potential marker. *Springerplus*. 2013;2:377.
4. Naumann M, Boo L, Ackerman A, et al. Immunogenicity of botulinum toxins. *J Neural Transm*. 2013;120(2):275-290.
5. Ramachandran R, Yaksh T. Therapeutic use of botulinum toxin in migraine: Mechanisms of action. *Br J Pharmacol*. 2014;171(18):4177-4192.
6. OH HM, Chung M. Botulinum toxin for neuropathic pain: A review of the literature. *Toxins (Base)*. 2015;7(8):3127–3154.
7. Headache Classification Committee of the International Headache Society (IHS). The International Headache Society 3rd edition (beta version);(ICHD-3 beta). *Cephalalgia*. 2013;33(9)629–808.
8. RimabotulinumtoxinB. Micromedex® DRUGDEX® Evaluations. Accessed August 24, 2016.
9. Lakraj A, Moghimi N, Jabbari B. Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins(Base)*. 2013;5(5):1010-1031.
10. Persaud, R, Garas G, Silva S, et al. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. *J R Soc Med Sh Rep* 2013;4:10.
11. Srivanichapoom P, Pandey S, Hallett M. Drooling in Parkinson's disease: A review. Parkinson's disease (PD) is a neurodegenerative disease causing both motor and non-motor symptoms. *Parkinsonism Relat Disord*. 2014;20(11):1109–1118.
12. Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. *Toxins*. 2015;7(5):1629-1648.
13. Elovic EP, Munin MC, Kanovsky P, et al: Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. *Muscle Nerve*. 2016; 53(3):415-421.
14. Product Information: XEOMIN(R) intramuscular injection powder, incobotulinumtoxinA intramuscular injection powder. Merz Pharmaceuticals, LLC (per manufacturer), Raleigh, NC, 2015
15. Esquenazi A, Alfaro A, Ayyoub Z, et al. OnabotulinumtoxinA for lower limb spasticity: Guidance from a Delphi panel approach. *PM&R*. 2017; 1-9.
16. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018. AbobotulinumtoxinA (Dysport). Accessed May 29, 2018.

17. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018. IncobotulinumtoxinA (Xeomin). Accessed May 29, 2018.
18. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018. OnabotulinumtoxinA (Botox). Accessed May 29, 2018.
19. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018. RimabotulinumtoxinB (Myobloc). Accessed May 29, 2018.
20. Aurora S, Dodick D, Diener H, et al., OnabotulinumtoxinA for Chronic Migraine: Efficacy, Safety, and Tolerability in Patients who Received All Five Treatment Cycles in the PREEMPT Clinical Program. *Acta Neurol Scand.* 2014;129:61-70.
21. Ranoux D, Martine G, Espagne-Debreuilh G, et al. OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain: an Observational, Open Label, Real-life Cohort Study. *J Headache Pain.* 2017;18:75-83.
22. Xeomin® (incobotulinumtoxinA) [package insert]. Merz Pharmaceuticals, LLC. Raleigh, NC. 12/2015.
23. Myobloc® (rimabotulinumtoxinB) [package insert]. Solstice Neurosciences, Inc. South San Francisco, CA. 05/2010.
24. Disport® (abobotulinumtoxinA) [package insert]. Ipsen Biopharm, Ltd. Wrexham, UK. 09/2017.
25. Botox® (onabotulinumtoxinA) [package insert]. Allergan, Inc. South Madison, NJ. 05/2018.